2023-06-29 15:12:29
Litfulo, a treatment for severe alopecia aerata has just been approved by the Food and Drug Administration. Designed by Pfizer, this drug has allowed patients to regain 80% of their hair coverage.
Mathieu Pourvendier
Written on 06/29/2023, updated on 06/29/2023
Severe alopecia aerata or alopecia areata is a severe form of alopecia where the hair loss is in the form of a patch without cooking localized hair — Shutterstock
The Food and Drug Administration (FDA) has given its approval for Litfulo (ritlecitinib), the laboratory announced Pfizer in a press release. This last one is “the first and onlyFDA-cleared treatment for this condition. The drug is for patients ages 12 and older with severe alopecia.
L‘alopecia is an autoimmune disease characterized by severe hair loss. Bald patches without scalp may appear. eyebrows, eyelashes and the fur face and other parts of the body are also affected. Severe alopecia aerata or alopecia areata is a severe form of alopecia. Normally this disease heals on its own, but sometimes it is chronic and requires treatment.
People “often misunderstood”
Symptoms of severe alopecia aerata normally begin in adolescence, according to Dr. Brittany Craiglow, assistant associate professor of Dermatology at Yale School of Medicine, cited in the statement. THE “litfulo is an especially important treatment option for younger patients with severe hair loss, who often struggle with such visible disease.“adds the dermatologist.
In effect, “leople with alopecia areata are often misunderstood and their experience is frequently trivialized as “just hair”. Yet it is a serious autoimmune disease that can have far-reaching negative consequences beyond the physical symptoms.“, attested Nicole Friedland, president and general manager of the National Alopecia Areata Foundation (NAAF) in the release.
Read also : Édouard Philippe, already suffering from vitiligo, announces that he suffers from alopecia
80% hair coverage regained
FDA clearance stems from positive ALLEGRO clinical trial result published on The Lancet. The drug was tested on 718 patients with hair loss of 50% or more. After 6 months of treatment, 23% of patients who received Litfulo regained 80% hair coverage compared to 1.6% with the placebo. The results were the same for children and adults. Moreover, fewside effects have been observed.
The “liftulo represents a significant advance in the treatment of alopecia areata, an autoimmune disease for which there have so far been no FDA-approved options for adolescents and limited options for adults. “, assured Angela Hwang, Chief Commercial Officer, President of Pfizer’s global biopharmaceutical business in the press release. She adds: “With today’s approval, teens and adults who struggle with severe hair loss have the opportunity to achieve significant scalp hair regrowth.“.
Pfizer announces that the treatment will be available in the coming weeks in the United States. With regard to France, the company did not communicate on the marketing of Litfulo on the territory.
1688056589
#Severe #alopecia #aerata #treatment #accepted #FDA